- Home
- HBANL vs RZLT Comparison
HBANL vs RZLT Comparison
Compare HBANL & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HBANL
Huntington Bancshares Incorporated Depositary Shares Each Representing a 1/40th Interest in a Share of 6.875% Series J Non-Cumulative Perpetual Preferred Stock
Current Price
Company Overview
Basic Information| Metric | HBANL | RZLT |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 471.0M |
| IPO Year | 2010 | 2011 |
Fundamental Metrics
Financial Performance| Metric | HBANL | RZLT |
|---|---|---|
| Price | $24.68 | $3.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $9.80 |
| AVG Volume (30 Days) | 27.0K | ★ 1.7M |
| Earning Date | N/A | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 13.93 | ★ 23.47 |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $1,562,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,214.20 |
| P/E Ratio | $98.73 | ★ N/A |
| Revenue Growth | ★ 6.40 | N/A |
| 52 Week Low | $24.31 | $1.07 |
| 52 Week High | $25.98 | $11.46 |
Technical Indicators
Market Signals| Indicator | HBANL | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 43.24 | 34.83 |
| Support Level | $24.65 | $2.91 |
| Resistance Level | $25.29 | $3.66 |
| Average True Range (ATR) | 0.24 | 0.35 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 22.23 | 14.61 |
Price Performance
Historical ComparisonAbout HBANL Huntington Bancshares Incorporated Depositary Shares Each Representing a 1/40th Interest in a Share of 6.875% Series J Non-Cumulative Perpetual Preferred Stock
Huntington Bancshares is a regional US bank with over $280 billion in assets. It offers a full suite of consumer deposit and lending services, along with commercial services focused on payments, investment management, capital markets, equipment financing, treasury management, and other common banking services.
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.